Renaissance Technologies LLC Cuts Position in Compass Pathways PLC Sponsored ADR $CMPS

Renaissance Technologies LLC lessened its position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 10.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 865,354 shares of the company’s stock after selling 102,492 shares during the quarter. Renaissance Technologies LLC’s holdings in Compass Pathways were worth $4,785,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Persistent Asset Partners Ltd bought a new stake in Compass Pathways during the fourth quarter worth about $38,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Compass Pathways during the 4th quarter valued at about $47,000. Advisory Services Network LLC purchased a new position in shares of Compass Pathways during the 3rd quarter valued at about $41,000. Parallel Advisors LLC raised its holdings in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares in the last quarter. Finally, North Star Investment Management Corp. lifted its position in Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after buying an additional 7,000 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $13.55 on Friday. The company has a market capitalization of $1.83 billion, a P/E ratio of -2.93 and a beta of 2.50. Compass Pathways PLC Sponsored ADR has a fifty-two week low of $3.97 and a fifty-two week high of $15.40. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The stock has a 50 day moving average price of $12.58 and a two-hundred day moving average price of $9.31.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

CMPS has been the topic of a number of recent research reports. Royal Bank Of Canada reduced their price target on shares of Compass Pathways from $22.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday. Stifel Nicolaus upped their price objective on shares of Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Wall Street Zen raised shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. B. Riley Financial lifted their target price on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Evercore upgraded shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price target for the company in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.71.

Compass Pathways News Summary

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: B. Riley raised its price target from $17 to $22 and assigned a “Buy” rating. The new target implies approximately 62% upside from the referenced share price, signaling increased confidence in Compass Pathways’ pipeline and the potential commercial opportunity for COMP360. Benzinga article
• Positive Sentiment: Management described the first half of 2026 as a defining period, citing continued momentum across clinical, regulatory and commercial activities as it prepares for the potential approval and launch of COMP360, its investigational mental-health treatment. Compass Pathways second-quarter results and business highlights
• Neutral Sentiment: Compass Pathways will participate in Canaccord Genuity’s 46th Annual Growth Conference on August 12. The presentation could provide updates on clinical development, regulatory plans and financing, but no new information was reported yet. Canaccord Genuity conference announcement
• Negative Sentiment: The company reported a second-quarter loss of $1.88 per share, missing the consensus estimate of a $0.39 loss by $1.49. Coverage also highlighted a wider year-over-year loss and higher operating expenses, which could increase concerns about cash burn even as Compass advances its development programs. Compass Pathways shares rise amid wider second-quarter loss

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.